Latest Articles
-
Abbott’s Collaboration With Department Of Defense Could Boost Diagnostics Sales
Abbott Laboratories (NYSE:ABT) recently announced a collaboration with the United States Department of Defense (DoD) to develop portable blood tests for the evaluation of mild traumatic brain injuries (TBIs). The tests would be specifically devel...
-
Abbott Raises Full Year Earnings Guidance On Strong Q2 Results
Healthcare giant Abbott Laboratories (NYSE:ABT) reported a strong set of second quarter 2014 results on Wednesday, July 16. The company’s operational sales increased 3% over the prior year quarter to $5.55 billion, beating analysts’ ...
-
Abbott Streamlines Generic Drug Business With Sale Of Developed Market Assets To Mylan
Global healthcare major Abbott Laboratories (NYSE:ABT) has entered into an agreement to sell a part of its generic drug business to specialty pharmaceuticals company Mylan (NASDAQ:MYL) in an all-stock deal. Mylan will acquire Abbott’s gene...
-
Abbott Earnings Preview: Recovery In Nutritionals, Growth In Emerging Markets To Drive Sales
Abbott Labs (NYSE:ABT) is scheduled to release its Q2 2014 earnings on Wednesday, July 16. In the previous quarter, sales declined by 2.5% year-over-year (y-o-y) to $5.24 billion, owing to sustained weakness in the Nutritionals and Established Ph...
-
Abbott Eyeing Growth In European Cataract Surgery Market With New Approval
Global healthcare giant Abbott Laboratories (NYSE:ABT) has received CE approval for its TECNIS Symfony extended range of vision intraocular lenses (IOL), used for the treatment of cataract patients who may also have difficulty focusing on close o...
-
Abbott Acquires Veropharm To Expand Presence In Russia
Global healthcare major Abbott Laboratories (NYSE:ABT) has agreed to acquire Russian pharmaceutical company Veropharm for between 13.6 billion and 17 billion rubles ($395 million – $495 million) in an all-cash deal. Veropharm is one of the ...
-
Abbott Looking To Revive Generic Drug Sales With CFR Acquisition
Healthcare major Abbott Laboratories (NYSE:ABT) has struggled to boost the sales of its generic drug business in recent years. Generic drugs are part of the company’s Established Pharmaceutical division, which generated revenue of about $5...
-
Abbott May Be Looking To Divest Part Of Generic Drug Business
Abbott Laboratories (NYSE:ABT) is reportedly considering divesting a significant part of its generic drug business, according to a recent Reuters report. The report also suggests that the healthcare major is working with Morgan Stanley to find a ...
-
Abbott’s Mixed Q1 Earnings Beat Estimates
Healthcare giant Abbott Laboratories (NYSE:ABT) reported a mixed set of first quarter 2014 results on Wednesday. The company’s sales saw a decline of about 2.5% year-over-year (y-o-y) to $5.24 billion, including an unfavorable foreign excha...
-
Abbott Earnings Preview: Emerging Markets & New Products Likely To Drive Sales
Abbott Labs (NYSE:ABT) is scheduled to release its Q1 2014 earnings on Wednesday, April 16. In the previous quarter, operational sales increased 3.3% year-over-year (y-o-y) to $5.7 billion, driven by robust sales of its Diagnostics, Vascular and ...
-
Diagnostics Continues To Drive Abbott’s Performance While Nutrition Remains Sluggish
Healthcare conglomerate Abbott Laboratories (NYSE:ABT) reported its Q4 2013 earnings on January 22. At $5.66 billion, fourth quarter worldwide sales increased 3.3% y-o-y on an operational basis. However, reported sales increased only 0.4% due to...
-
Abbott Earnings Preview: Steady Growth Expected Despite Short Term Weakness In Nutritionals
Abbott Labs (NYSE:ABT) is scheduled to release its Q4 2013 earnings on Wednesday, January 22. In the previous quarter, the company reported a 4.3% year-over-year increase in operational sales as Diagnostics, Abbott’s second largest business...
-
Abbott Had A Transformational 2013, Here’s What To Expect in 2014
Abbott Labs (NYSE:ABT) started 2013 by spinning off its proprietary pharmaceutical business as Abbvie (NYSE:ABBV) on January 1, 2013. With the move, the company began a new life as a healthcare firm whose major offerings include nutritional, diag...
-
A Look At Abbott’s Vascular Division
Abbott Labs (NYSE:ABT) is one of the largest healthcare firms in the U.S. It spun off its proprietary pharmaceutical division as Abbvie (NYSE:ABBV) earlier this year and is now left with four main business divisions – Nutritionals, Diagnostics, V...
-
Boston Scientific Earnings: Key Businesses Stabilizing, More Cost Cutting To Come
Boston Scientific (NYSE:BSX) released its earnings for Q3 on October 24. The company’s results reflect the same story that has played out so far this year – its smaller divisions are growing fast, while two of its largest divisions, Cardiac Rhyth...
